1. Home
  2. NOTV vs DBVT Comparison

NOTV vs DBVT Comparison

Compare NOTV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • DBVT
  • Stock Information
  • Founded
  • NOTV 1974
  • DBVT 2002
  • Country
  • NOTV United States
  • DBVT France
  • Employees
  • NOTV N/A
  • DBVT N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NOTV Health Care
  • DBVT Health Care
  • Exchange
  • NOTV Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • NOTV 126.3M
  • DBVT 102.0M
  • IPO Year
  • NOTV 1997
  • DBVT N/A
  • Fundamental
  • Price
  • NOTV $4.27
  • DBVT $4.47
  • Analyst Decision
  • NOTV Strong Buy
  • DBVT Strong Buy
  • Analyst Count
  • NOTV 3
  • DBVT 2
  • Target Price
  • NOTV $5.92
  • DBVT $22.50
  • AVG Volume (30 Days)
  • NOTV 1.2M
  • DBVT 141.9K
  • Earning Date
  • NOTV 02-05-2025
  • DBVT 03-06-2025
  • Dividend Yield
  • NOTV N/A
  • DBVT N/A
  • EPS Growth
  • NOTV N/A
  • DBVT N/A
  • EPS
  • NOTV N/A
  • DBVT N/A
  • Revenue
  • NOTV $490,739,000.00
  • DBVT $12,515,000.00
  • Revenue This Year
  • NOTV $7.14
  • DBVT N/A
  • Revenue Next Year
  • NOTV $5.73
  • DBVT $2,860.00
  • P/E Ratio
  • NOTV N/A
  • DBVT N/A
  • Revenue Growth
  • NOTV N/A
  • DBVT 125.54
  • 52 Week Low
  • NOTV $1.23
  • DBVT $0.44
  • 52 Week High
  • NOTV $11.42
  • DBVT $5.42
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 49.19
  • DBVT 61.49
  • Support Level
  • NOTV $3.87
  • DBVT $4.30
  • Resistance Level
  • NOTV $4.67
  • DBVT $5.15
  • Average True Range (ATR)
  • NOTV 0.54
  • DBVT 0.41
  • MACD
  • NOTV -0.10
  • DBVT 0.06
  • Stochastic Oscillator
  • NOTV 22.22
  • DBVT 60.70

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: